Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy

European Journal of Neurology

Volumn 20, Issue 12, 2013, Pages 1539-1545

  Lozeron, P ^a   Theaudin M ^a   Mincheva, Z ^a   Ducot, B ^a   Lacroix, C ^a   Adams, D ^a  

^a BICÊTRE HOSPITAL   (France)

Author keywords

Familial amyloid polyneuropathy; Met30 TTR FAP; Tafamidis; Vyndaqel

Indexed keywords

PREALBUMIN; TAFAMIDIS;

ABDOMINAL PAIN; ACUTE HEART INFARCTION; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FAMILIAL AMYLOID POLYNEUROPATHY; FECES INCONTINENCE; FOLLOW UP; HEMATURIA; HUMAN; LIMB PAIN; LUNG INFECTION; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; URINARY TRACT INFECTION; URINE INCONTINENCE; WALKING DIFFICULTY;

FAMILIAL AMYLOID POLYNEUROPATHY; MET30 TTR-FAP; TAFAMIDIS; VYNDAQEL;

AGED; AMYLOID NEUROPATHIES, FAMILIAL; BENZOXAZOLES; DISEASE PROGRESSION; HUMANS; MIDDLE AGED;

EID: 84887402882     PISSN: 13515101     EISSN: 14681331     Source Type: Journal    
DOI: 10.1111/ene.12225     Document Type: Article

References (26)

1. Adams D. Hereditary and acquired amyloid neuropathies. J Neurol 2001; 248: 647-657.
2. Coutinho P, Martins da Silva A, Lopes Lima J, et al. Forty years of experience with type I amyloid polyneuropathy. Review of 483 cases. In: Glenner G, Pinho e Costa P, Falcao de Freitas A, eds. Amyloid Ans Amyloidosis. Amsterdam: Excerpta Medica, 1980: 88-98.
3. Holmgren G, Ericzon BG, Groth CG, et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113-1116.
4. Adams D, Samuel D, Goulon-Goeau C, et al. The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation. Brain 2000; 123(Pt 7): 1495-1504.
5. Yamamoto S, Wilczek HE, Nowak G, et al. Liver transplantation for familial amyloidotic polyneuropathy (FAP): a single-center experience over 16 years. Am J Transplant 2007; 7: 2597-2604.
6. Yamashita T, Ando Y, Okamoto S, et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy. Neurology 2012; 78: 637-643.
7. Wilczek HE, Larsson M, Ericzon BG. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR). Amyloid 2011; 18(Suppl. 1): 188-190.
8. Yang NC, Lee MJ, Chao CC, et al. Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser. Neurology 2010; 75: 532-538.
9. Luigetti M, Conte A, Del Grande A, et al. TTR-related amyloid neuropathy: clinical, electrophysiological and pathological findings in 15 unrelated patients. Neurol Sci 2012; 34: 1057-1063.
10. Cappellari M, Cavallaro T, Ferrarini M, et al. Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients. J Peripher Nerv Syst 2011; 16: 119-129.
11. Adams D, Lozeron P, Theaudin M, et al. Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 2012; 19(Suppl. 1): 61-64.
12. Johnson SM, Connelly S, Fearns C, Powers ET, Kelly JW. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J Mol Biol 2012; 421: 185-203.
13. Coelho T, Maia LF, Martins da Silva A, et al. Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785-792.
14. Bril V. NIS-LL: the primary measurement scale for clinical trial endpoints in diabetic peripheral neuropathy. Eur Neurol 1999; 41(Suppl. 1): 8-13.
15. Steen L, Ek B. Familial amyloidosis with polyneuropathy. A long-term follow-up of 21 patients with special reference to gastrointestinal symptoms. Acta Med Scand 1983; 214: 387-397.
16. Denier C, Ducot B, Husson H, et al. A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy. J Neurol 2007; 254: 1684-1688.
17. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220-2224.
18. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.
19. Diabetic polyneuropathy in controlled clinical trials: Consensus Report of the Peripheral Nerve Society. Ann Neurol 1995;38:478-482.
20. European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002294/WC500117838.pdf. (accessed 25/06/2013)
21. Koike H, Tanaka F, Hashimoto R, et al. Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 2012; 83: 152-158.
22. Shirota Y, Iwata A, Ishiura H, et al. A case of atypical amyloid polyneuropathy with predominant upper-limb involvement with the diagnosis unexpectedly found at lung operation. Intern Med 2010; 49: 1627-1631.
23. Adams D, Lozeron P, Lacroix C. Amyloid neuropathies. Curr Opin Neurol 2012; 25: 564-572.
24. Ackermann EJ, Guo S, Booten S, et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 2012; 19(Suppl. 1): 43-44.
25. Coelho T, Suhr O, Adams D, et al. Interim clinical update for ALN-TTR01, a novel RNAI therapeutic for the treatment of transthyretin amyloidosis. J Peripher Nerv Syst 2011; 16: S25.
26. Obici L, Cortese A, Lozza A, et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19(Suppl. 1): 34-36.